본문 바로가기

Survival Outcomes Associated with the Location of BRCA Mutations in Ovarian Cancer: A Systematic Review and Meta-Analysis

문서 유형
연구출판물 · 리뷰논문
등재
SCIEScopus
저널 순위
JCR Q2Scopus Q1
저널
CANCERS17(10) · #1661 · 2025
피인용
Web of Science 3Scopus 3
FWCI (Scopus)
0.22
JCR IF
JCR 2024 4.4
ISSN
2072-6694

저자

  1. Kim, Ji Hyun제1저자Natl Canc Ctr, Res Inst & Hosp, Ctr Gynecol Canc, Goyang 10408, South Korea
  2. 윤형준Pusan Natl Univ Hosp, Dept Obstet & Gynecol, Busan 49241, South Korea
  3. 하형인Pusan Natl Univ, Coll Med, Dept Obstet & Gynecol, Busan 49241, South Korea
  4. Kim, Eun TaegKosin Univ, Gospel Hosp, Coll Med, Dept Obstet & Gynecol, Busan 49267, South Korea
  5. Kim, Dongkyu EugeneNatl Canc Ctr, Res Inst & Hosp, Ctr Gynecol Canc, Goyang 10408, South Korea
  6. Kim, SangeonNatl Canc Ctr, Res Inst & Hosp, Ctr Gynecol Canc, Goyang 10408, South Korea
  7. Bae, Jae KyungNatl Canc Ctr, Res Inst & Hosp, Ctr Gynecol Canc, Goyang 10408, South Korea
  8. Lim, Myong Cheol교신저자Natl Canc Ctr, Res Inst & Hosp, Ctr Gynecol Canc, Goyang 10408, South Korea

초록

Background/Objective: BRCA1 and BRCA2 genes contain functional domains that operate at different stages of the DNA damage response. Although studies have suggested that the location of BRCA1/2 mutations may influence clinical outcomes, no discernible pattern has been observed indicating which mutation location influences clinical outcomes in patients with ovarian cancer with BRCA1/2 mutations. Therefore, this study aimed to evaluate the differences in survival outcomes between BRCA1/2 mutation locations, with a specific focus on exon 11, in patients with epithelial ovarian cancer. Methods: A comprehensive literature review was conducted using PubMed, Embase, and Cochrane Library databases, including articles published up to 13 August 2024. Progression-free survival (PFS) and overall survival (OS) were assessed based on the BRCA mutation location, with subgroup analyses focusing on exon 11 mutations in BRCA1 and BRCA2. Statistical heterogeneity was evaluated using the I2 index. Results: Seven studies involving 1535 patients were included. BRCA2 exon 11 mutations demonstrated a significant PFS advantage (HR, 0.586; 95% CI, 0.346-0.994, I2 = 55%), whereas BRCA1 exon 11 mutations had no significant effect on PFS or OS. Conclusions: These findings suggest differential prognostic outcomes based on the BRCA mutation location, highlighting the clinical relevance of BRCA2 exon 11. BRCA2 exon 11 mutations were associated with improved PFS, which underscores the prognostic significance of the BRCA mutation location, particularly exon 11, in ovarian cancer. These findings reinforce the biological relevance of exon 11 by consolidating evidence from multiple studies that suggest potential prognostic implications of mutations within this region.

키워드

BRCA1BRCA2exon 11ovarian cancersurvival outcomesmeta-analysisGERMLINE MUTATIONSBREASTGENEMAINTENANCEBEVACIZUMABPHENOTYPEOLAPARIBRISKS

식별자

Scopus EID
2-s2.0-105006550151
WoS UID
001495572100001